Patents by Inventor Stacey Dillon
Stacey Dillon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230241168Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers) alone, or also coupled with inhibition of T cell costimulation. The immunomodulatory proteins provided herein include variant domains of B cell maturation antigen (BCMA) alone, or multi-domain immunomodulatory protein that inhibit B cell responses and also can inhibit T cell costimulation. Also provided are nucleic acids molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases or conditions. Also provided are compositions and methods for making and using such proteins.Type: ApplicationFiled: May 7, 2021Publication date: August 3, 2023Applicant: Alpine Immune Sciences, Inc.Inventors: Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG, Ryan SWANSON
-
Patent number: 11274140Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.Type: GrantFiled: June 11, 2021Date of Patent: March 15, 2022Assignee: Alpine Immune Sciences, Inc.Inventors: Stacey Dillon, Mark Rixon, Lawrence Evans, Daniel William Demonte, Joseph L. Kuijper, Stanford L. Peng
-
Publication number: 20210388054Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.Type: ApplicationFiled: May 7, 2021Publication date: December 16, 2021Applicant: Alpine Immune Sciences, Inc.Inventors: Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG
-
Publication number: 20210363223Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.Type: ApplicationFiled: June 11, 2021Publication date: November 25, 2021Applicant: Alpine Immune Sciences, Inc.Inventors: Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG
-
Publication number: 20070298037Abstract: Novel tumor necrosis factor receptor (TNFR) polypeptides, polynucleotides encoding the polypeptides, antibodies and related compositions and methods are disclosed. The polypeptides may be used for detecting ligand, as well as agonists and antagonists. The polypeptides, polynucleotides and antibodies may also be used in methods that modulate tumor growth, metastasis, and immunity such as separating resting from stimulated immune cells.Type: ApplicationFiled: November 6, 2006Publication date: December 27, 2007Inventors: Brian Fox, James Holloway, Paul Sheppard, Stacey Dillon
-
Publication number: 20070166794Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: ApplicationFiled: October 23, 2006Publication date: July 19, 2007Inventors: Julia Novak, Scott Presnell, Cindy Sprecher, Donald Foster, Richard Holly, Jane Gross, Janet Johnston, Andrew Nelson, Stacey Dillon, Angela Hammond
-
Publication number: 20070140963Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.Type: ApplicationFiled: October 26, 2006Publication date: June 21, 2007Inventors: Cindy Sprecher, Zeren Gao, Joseph Kuijper, Maria Dasovich, Francis Grant, Scott Presnell, Theodore Whitmore, Angela Hammond, Julia Novak, Jane Gross, Stacey Dillon
-
Publication number: 20070140964Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.Type: ApplicationFiled: October 26, 2006Publication date: June 21, 2007Inventors: Cindy Sprecher, Zeren Gao, Joseph Kuijper, Maria Dasovich, Francis Grant, Scott Presnell, Theodore Whitmore, Angela Hammond, Julia Novak, Jane Gross, Stacey Dillon
-
Publication number: 20070111945Abstract: The use of corticotroph-derived glycoprotein hormone (CGH) to potentiate glucocorticoid action and to reduce glucocorticoid-induced adrenocortical suppression is described. CGH can be co-administered with glucocorticoids to enable a lower dosage of glucocorticoids to be used and to prevent or reduce glucocorticoid-induced side-effects. The invention additionally provides methods for the use of CGH as a replacement for glucocorticoids, or for treatment of a broad range of inflammatory states. Further provided are methods for purification of recombinant CGH.Type: ApplicationFiled: November 22, 2006Publication date: May 17, 2007Inventors: James Kelly, Philippa Webster, Stacey Dillon, Shannon O'Hogan
-
Publication number: 20070099269Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: ApplicationFiled: October 16, 2006Publication date: May 3, 2007Inventors: JULIA NOVAK, Scott Presnell, Cindy Sprecher, Donald Foster, Richard Holly, Jane Gross, Janet Johnston, Andrew Nelson, Stacey Dillon, Angela Hammond
-
Publication number: 20070098683Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: ApplicationFiled: October 19, 2006Publication date: May 3, 2007Inventors: Julia Novak, Scott Presnell, Cindy Sprecher, Donald Foster, Richard Holly, Jane Gross, Janet Johnston, Andrew Nelson, Stacey Dillon, Angela Hammond
-
Publication number: 20070098682Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: ApplicationFiled: October 19, 2006Publication date: May 3, 2007Inventors: Julia Novak, Scott Presnell, Cindy Sprecher, Donald Foster, Richard Holly, Jane Gross, Janet Johnston, Andrew Nelson, Stacey Dillon, Angela Hammond
-
Publication number: 20070092485Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: ApplicationFiled: October 23, 2006Publication date: April 26, 2007Inventors: JULIA NOVAK, Scott Presnell, Cindy Sprecher, Donald Foster, Richard Holly, Jane Gross, Janet Johnston, Andrew Nelson, Stacey Dillon, Angela Hammond
-
Publication number: 20070066807Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: ApplicationFiled: October 20, 2006Publication date: March 22, 2007Inventors: JULIA NOVAK, Scott Presnell, Cindy Sprecher, Donald Foster, Richard Holly, Jane Gross, Janet Johnston, Andrew Nelson, Stacey Dillon, Angela Hammond
-
Publication number: 20070066808Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: ApplicationFiled: October 23, 2006Publication date: March 22, 2007Inventors: JULIA NOVAK, Scott Presnell, Cindy Sprecher, Donald Foster, Richard Holly, Jane Gross, Janet Johnston, Andrew Nelson, Stacey Dillon, Angela Hammond
-
Publication number: 20070059825Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: ApplicationFiled: October 19, 2006Publication date: March 15, 2007Inventors: Julia Novak, Scott Presnell, Cindy Sprecher, Donald Foster, Richard Holly, Jane Gross, Janet Johnston, Andrew Nelson, Stacey Dillon, Angela Hammond
-
Publication number: 20070054320Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: ApplicationFiled: October 19, 2006Publication date: March 8, 2007Inventors: Julia Novak, Scott Presnell, Cindy Sprecher, Donald Foster, Richard Holly, Jane Gross, Janet Johnston, Andrew Nelson, Stacey Dillon, Angela Hammond
-
Publication number: 20070048259Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: ApplicationFiled: October 20, 2006Publication date: March 1, 2007Inventors: Julia Novak, Scott Presnell, Cindy Sprecher, Donald Foster, Richard Holly, Jane Gross, Janet Johnston, Andrew Nelson, Stacey Dillon, Angela Hammond
-
Publication number: 20070048835Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.Type: ApplicationFiled: October 25, 2006Publication date: March 1, 2007Inventors: Cindy Sprecher, Zeren Gao, Joseph Kuijper, Maria Dasovich, Francis Grant, Scott Presnell, Theodore Whitmore, Angela Hammond, Julia Novak, Jane Gross, Stacey Dillon
-
Publication number: 20070048223Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.Type: ApplicationFiled: October 27, 2006Publication date: March 1, 2007Inventors: Cindy Sprecher, Zeren Gao, Joseph Kuijper, Maria Dasovich, Francis Grant, Scott Presnell, Theodore Whitmore, Angela Hammond, Julia Novak, Jane Gross, Stacey Dillon